Olga G Grushko1,2, Steven Cho1,2, Ashley M Tate1,2, Robert S Rosenson3, David J Pinsky1,2, Jacob M Haus4, Scott L Hummel1,2,5, Sascha N Goonewardena6,7,8. 1. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2. University of Michigan Frankel Cardiovascular Center, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI, 48109-5853, USA. 3. Metabolism and Lipids Unit, Icahn School of Medicine at Mount Sinai, Cardiovascular Institute, Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai, NY, USA. 4. School of Kinesiology, University of Michigan, Ann Arbor, MI, USA. 5. VA Ann Arbor Health System, Ann Arbor, MI, USA. 6. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. sngoonew@med.umich.edu. 7. University of Michigan Frankel Cardiovascular Center, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI, 48109-5853, USA. sngoonew@med.umich.edu. 8. VA Ann Arbor Health System, Ann Arbor, MI, USA. sngoonew@med.umich.edu.
Abstract
PURPOSE: Acute heart failure (AHF) syndromes manifest increased inflammation and vascular dysfunction; however, mechanisms that integrate the two in AHF remain largely unknown. The glycocalyx (GAC) is a sugar-based shell that envelops all mammalian cells. Much GAC research has focused on its role in vascular responses, with comparatively little known about how the GAC regulates immune cell function. METHODS: In this study, we sought to determine if GAC degradation products are elevated in AHF patients, how these degradation products relate to circulating inflammatory mediators, and whether the monocyte GAC (mGAC) itself modulates monocyte activation. Inflammatory markers and GAC degradation products were profiled using ELISAs. Flow cytometry was used to assess the mGAC and RNA-seq was employed to understand the role of the mGAC in regulating inflammatory activation programs. RESULTS: In a cohort of hospitalized AHF patients (n = 17), we found that (1) the GAC degradation product heparan sulfate (HS) was elevated compared with age-matched controls (4396 and 2903 ng/mL; p = 0.01) and that (2) HS and soluble CD14 (a marker of monocyte activation) levels were closely related (Pearson's r = 0.65; p = 0.002). Mechanistically, Toll-like receptor (TLR) activation of human monocytes results in GAC remodeling and a decrease in the mGAC (71% compared with no treatment; p = 0.0007). Additionally, we found that ex vivo enzymatic removal of HS and disruption of the mGAC triggers human monocyte activation and amplifies monocyte inflammatory responses. Specifically, using RNA-seq, we found that enzymatic degradation of the mGAC increases transcription of inflammatory (IL6, CCL3) and vascular (tissue factor/F3) mediators. CONCLUSION: These studies indicate that the mGAC is dynamically remodeled during monocyte activation and that mGAC remodeling itself may contribute to the heightened inflammation associated with AHF.
PURPOSE: Acute heart failure (AHF) syndromes manifest increased inflammation and vascular dysfunction; however, mechanisms that integrate the two in AHF remain largely unknown. The glycocalyx (GAC) is a sugar-based shell that envelops all mammalian cells. Much GAC research has focused on its role in vascular responses, with comparatively little known about how the GAC regulates immune cell function. METHODS: In this study, we sought to determine if GAC degradation products are elevated in AHF patients, how these degradation products relate to circulating inflammatory mediators, and whether the monocyte GAC (mGAC) itself modulates monocyte activation. Inflammatory markers and GAC degradation products were profiled using ELISAs. Flow cytometry was used to assess the mGAC and RNA-seq was employed to understand the role of the mGAC in regulating inflammatory activation programs. RESULTS: In a cohort of hospitalized AHF patients (n = 17), we found that (1) the GAC degradation product heparan sulfate (HS) was elevated compared with age-matched controls (4396 and 2903 ng/mL; p = 0.01) and that (2) HS and soluble CD14 (a marker of monocyte activation) levels were closely related (Pearson's r = 0.65; p = 0.002). Mechanistically, Toll-like receptor (TLR) activation of human monocytes results in GAC remodeling and a decrease in the mGAC (71% compared with no treatment; p = 0.0007). Additionally, we found that ex vivo enzymatic removal of HS and disruption of the mGAC triggers human monocyte activation and amplifies monocyte inflammatory responses. Specifically, using RNA-seq, we found that enzymatic degradation of the mGAC increases transcription of inflammatory (IL6, CCL3) and vascular (tissue factor/F3) mediators. CONCLUSION: These studies indicate that the mGAC is dynamically remodeled during monocyte activation and that mGAC remodeling itself may contribute to the heightened inflammation associated with AHF.
Authors: Brendan M Everett; Jan H Cornel; Mitja Lainscak; Stefan D Anker; Antonio Abbate; Tom Thuren; Peter Libby; Robert J Glynn; Paul M Ridker Journal: Circulation Date: 2019-03-05 Impact factor: 29.690
Authors: Paolo C Colombo; Duygu Onat; Ante Harxhi; Ryan T Demmer; Yacki Hayashi; Sanja Jelic; Thierry H LeJemtel; Loredana Bucciarelli; Moritz Kebschull; Panos Papapanou; Nir Uriel; Ann Marie Schmidt; Hani N Sabbah; Ulrich P Jorde Journal: Eur Heart J Date: 2013-11-20 Impact factor: 29.983
Authors: Sascha N Goonewardena; Adam B Stein; Ryan E Tsuchida; Rahul Rattan; Dhavan Shah; Scott L Hummel Journal: J Card Fail Date: 2015-12-17 Impact factor: 5.712
Authors: Jianrui Song; Ryan A Frieler; Thomas M Vigil; Jun Ma; Frank Brombacher; Sascha N Goonewardena; Daniel R Goldstein; Richard M Mortensen Journal: J Am Heart Assoc Date: 2021-06-16 Impact factor: 5.501